Everts-Graber and colleagues report a higher rate of osteonecrosis of the jaw in osteoporosis patients “under treatment” with denosumab (12 of 4,326, or 28.3 cases per 10,000 person-years ...

Osteonecrosis of the jaw can be a serious health issue without proper treatment. Speak with a doctor if you have factors in your life that put you at risk and about what signs to be on the lookout ...

However, the risk of ONJ for osteoporosis patients taking these types of drugs is very low - much lower than the risk of breaking a bone. Most of the people who have gotten ONJ while taking ...

With the risk of ONJ for oral bisphosphonate users apparently falling somewhere in the 1 in 100,000 patient-treatment-years range, the risk-benefit analysis is an easy one, Shane said.

A patient receiving antiresorptive therapy for the prevention and treatment of osteoporosis has a low risk of developing osteonecrosis of the jaw (ONJ), and benefits of the medication outweigh the ...

The risk for ONJ with denosumab appears to be comparable to that seen with high-dose intravenous zoledronic acid, Dr. Van Poznak said.

Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing osteonecrosis of the jaw (ONJ) in patients who take ...

Overall, there were 13 women who had ONJ over the 7-year extension trial out of 1,621 participants -- 11 occurring in women with invasive oral events, one in a woman without such an event, and one ...

The only significant risk factor for ONJ was the type of bisphosphonate (P=0.006). The incidence of ONJ was significantly higher with ZA than with pamidronate + ZA (9.1 vs 1.6 per 100 person-years).

CHICAGO — New data highlight the risk for osteonecrosis of the jaw (ONJ) in cancer patients who take bone-modifying agents to reduce the risk for skeletal events associated with bone metastases ...